Skip to main content

Rapivir (Rapamycin) aka Magic Medicine

Magic Medicine Rapivir (Rapamycin) Pathway Target Confirmed

Dr. George Thomas and Dr. Sara Kozma of the Bellvitge Institute of Biomedical Research and the University of Barcelona reported online in Nature on February 8 that S6K1 has a glutamyl-prolyl tRNA synthetase molecule (EPRS) from inhibiting translation to transferring fatty acids The role of reorientation.

The study was conducted in collaboration with researchers at the Cleveland Clinic and the University of Illinois, and may lead to the development of biomarkers and targeted therapies for obesity and aging.


Rapamycin complex 1 (mTORC1) and p70 ribosomal protein S6 kinase (S6K1)

The metabolic pathways associated with obesity and aging in mammals are activated by rapamycin complex 1 (mTORC1) and p70 ribosomal protein S6 kinase (S6K1).

However, the target of mTORC1–S6K1 is not related to the observed loss of phenotypic function, which suggests that there are other downstream effectors in this pathway.


EPRS is target of mTORC1–S6K1

Previous studies by Dr. Thomas and Kozma have shown that S6K1 plays a key role in the expansion of adipose tissue that differentiates mesenchymal stem cells into adipocytes through transcriptional regulation.

This new study confirms that EPRS is the target of mTORC1–S6K1 and is associated with obesity and aging processes. Dr. Thomas explained:

"Corresponding author Paul Fox contacted us and suggested that S6K1 and EPRS may have a connection. Together we discovered that S6K1 phosphorylation requires EPRS to be released from the typical role of protein synthesis."

 

Medicinal Drug Rapivir

The phosphorylation of EPRS caused by mTORC1–S6K1 at Ser999 induces its release from the aminoacyl tRNA synthetase complex, which is an atypical function of EPRS outside of protein synthesis.


To investigate the physiological role of EPRS phosphorylation

The researchers prepared transgenic mice with mutations in Ser999. Ser999 phosphate-deficient mice exhibited low body weight, reduced body fat content and extended lifespan, indicating that phosphorylation mediates S6K1 dependent metabolic reactions.


 EPRS mediates fatty acid transporter 1 (FATP1) localization

Dr. Kozma added: This functional shift is key, because we also found that EPRS mediates fatty acid transporter 1 (FATP1) localization on the cell membrane and stimulates the absorption of long-chain fatty acids.

This confirms that S6K1 leads to obesity and aging Double action.

In fact, EPRS mutant phosphorus-deficient mice produce the same physical characteristics (phenotype) as S6K1-deficient mice:

Low body weight, reduced mass of adipose tissue, and extended lifespan. These results reinforce the concept, S6K1 Can be used as a predictor of obesity or as a drug target to suppress obesity.


Tags: #Rapivir #Ramivir #Lamivir #EPRSphosphorylation #MagicMedicine #MagicDrug

Comments

Popular posts from this blog

Difference Between COVID-19 Coronavirus and Other Flu Epidemic Infections

What are the differences between COVID-19 and the flu epidemic?The epidemic caused by the new Coronavirus (2019-nCoV) is still spreading. This disease, which has just been officially named COVID-19, has caused more than 40,000 infections and more than 1,000 deaths. At the same time, on the other side of the ocean, another epidemic also attracted people's attention. The flu season in the United States is on schedule. 
According to data released by the US Centers for Disease Control and Prevention, as of February 1, 22 million to 31 million people are expected to be infected during the flu season, and the number of patients dying from influenza is between 12,000 and 30,000. 
Seeing such figures, some readers may be surprised when they think: Is the flu epidemic in the United States worse? What are the differences between COVID-19 and the flu epidemic? Is this really the case? What are the differences between COVID-19 and the flu epidemic?
The facts are being unraveled below: 1. Unknown ris…

FDA Launches New Website to Encourage COVID-19 Rehabilitation Patients to Donate Plasma

According to foreign media TechCrunch, one of the ways currently being sought to develop effective treatments for COVID-19 is to use convalescent plasma. Basically, this means using plasma from COVID-19 patients who have fully recovered, hoping to transfer the antibodies they produced during the fight against the virus to others. 

US Food and Drug Administration (FDA) creates dedicated website to seek recovery plasma donationsThe US Food and Drug Administration (FDA) has created a dedicated new website that seeks recovery plasma donations from COVID-19 rehabilitation patients and explains their potential uses.
The use of plasma during recovery is hardly a new concept. In fact, it has been used since the late 1890s and was used during the Spanish influenza pandemic in 1918, although "the results were mixed."
Modern methods can help improve the efficacy and potential of recovered plasma as a therapeutic method. There are currently some drugs under development that use plasma (ani…

Physiological and Pathological Mosquitoe Floaters

What are the differences between physiological floaters and pathological floaters?What are the differences between physiological and pathological flying mosquitoes after the birth of a child? What are the differences between physiological and pathological flying mosquitoes? Experts believe everyone can guess literally. It is true that this is an ophthalmological disease. People with flying mosquitoes will have dark shadows shaking in front of their eyes when they are looking at things, and the vision is not clear, and flying mosquitoes can beFlying Mosquitoes
Mentioned flying mosquitoes, I believe everyone can literally guess that this is an ophthalmic disease, the fact is true. Patients with flying mosquitoes will have black shadows swaying in front of their eyes when watching things, and the vision is unclear.
Flying mosquitoes can be divided into physiological and pathological types. Below I will introduce you to physiological flying mosquitoes and The difference between pathologica…